新辅助化疗反应良好的儿童鼻咽癌减剂量放疗的可行性
本研究回顾性分析132例≤18岁局部晚期鼻咽癌患儿,均在新辅助化疗2-4周期后肿瘤反应良好并接受同步放化疗,比较原发灶标准放疗剂量66-72 Gy与减量放疗剂量60-65.9 Gy的生存结局与治疗相关毒性。减量组严重口腔黏膜炎发生率和严重后遗症总发生率显著低于标准组,倾向性匹配分析中两组5年生存结局平行。
要点
- 减量组严重口腔黏膜炎发生率为32.1%,标准组为51.3%(P=0.034)。
- 减量组严重后遗症总发生率为13.7%,标准组为31.8%(P=0.029)。
- 倾向性匹配分析中两组5年无病生存、总生存、无远处转移生存及无局部区域复发生存均无显著差异。
核心结论
- 对于新辅助化疗后肿瘤反应良好的儿童及青少年局部晚期鼻咽癌,同步放化疗中原发灶放疗剂量为60-65.9 Gy可能是合理的策略。
研究设计与样本
- 基于鼻咽癌专用数据库的回顾性分析,纳入≤18岁局部晚期鼻咽癌患者,均接受2-4周期新辅助化疗后肿瘤反应良好并后续同步放化疗,共132例,中位随访75.2个月(IQR 53.2-98.7个月)。
主要发现
- 减量组严重口腔黏膜炎发生率为32.1%,标准组为51.3%(P=0.034),减量组较标准组降低。
- 减量组严重后遗症总发生率为13.7%,标准组为31.8%(P=0.029),减量组较标准组降低。
- 倾向性匹配分析中,减量组与标准组5年无病生存率分别为82.7%与80.3%(P=0.841),总生存率分别为91.7%与91.3%(P=0.582),无远处转移生存率分别为87.5%与82.8%(P=0.573),无局部区域复发生存率分别为95.6%与97.3%(P=0.836),均无显著差异。
- 多因素分析中,减量放疗对所有生存终点的影响仍无统计学意义。
关键数值与推荐
- 原发灶标准放疗剂量为66-72 Gy,减量放疗剂量为60-65.9 Gy。
- 新辅助化疗周期数为2-4周期。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To assess the feasibility of adjusting radiation dose (RD) in childhood NPC with favorable tumor response after neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS: Using an NPC-specific database, children and adolescents (≤18 years) with locoregionally advanced NPC (CA-LANPC) were retrospectively analyzed. Enrolled patients were those who received favorable tumor response after 2-4 cycles of NAC followed by concurrent chemoradiotherapy. Survival outcomes and treatment-related toxicities were compared for the standard RD on primary tumors (PT-RDstandard, 66-72 Gy) and the reduced RD on primary tumors (PT-RDreduced, 60-65.9 Gy). RESULTS: A total of 132 patients were included, and the median follow-up time was 75.2 months (IQR, 53.2-98.7 months) for the entire cohort. The PT-RDreduced group had a significantly decreased incidence of severe mucositis (51.3 % vs 32.1 %; P = 0.034) when compared to the PT-RDstandard group. The total incidence of severe sequela in the PT-RDstandard group were significantly higher than those in the PT-RDreduced group (31.8 % vs 13.7 %; P = 0.029). In the propensity-matched analysis, the PT-RDreduced group resulted in parallel 5-year survival with the PT-RDstandard group from the matched cohort (disease-free survival, 82.7 % vs 80.3 %, P = 0.841; overall survival, 91.7 % vs 91.3 %, P = 0.582; distant metastasis-free survival, 87.5 % vs 82.8 %, P = 0.573; and locoregional relapse-free survival, 95.6 % vs 97.3 %, P = 0.836). In multivariate analysis, the impact of PT-RDreduced on all survival end points remained insignificant. CONCLUSIONS: Chemoradiotherapy with RD at levels of 60-65.9 Gy may be a reasonable strategy for CA-LANPC with favorable tumor response after NAC.
引用
- Yao JJ, Jin YN, Lin YJ, et al. The feasibility of reduced-dose radiotherapy in childhood nasopharyngeal carcinoma with favorable response to neoadjuvant chemotherapy. Radiother Oncol. 2022. PMID: 36375563. doi:10.1016/j.radonc.2022.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。